Aptiv price prediction for 7/19

**Aptiv's stock price is likely to face downward pressure in the short term**, with a potential drop from its current price of $69.44 to $56.75, representing a -19.28% change. This forecast is based on historical data and market trends, which suggest that the stock may continue to experience volatility.

1. **Analyst Price Targets**:
- The average 12-month price target from 9 Wall Street analysts is $105.14, with a high forecast of $145.00 and a low of $83.00.
- Another set of 12-month price targets from 11 analysts has an average of $111.33, with a low estimate of $74 and a high estimate of $145.
- Short-term price targets from 17 analysts give an average of $101.12.

|code|stock code|stock name|last-price|last-change|Average Price Target[20240701]|Average Price Target rank[20240701]|market_code|
|---|---|---|---|---|---|---|---|
|NVR|NVR.N|NVR|7460.7000|-0.2868|8175|1/6176|169|

2. **Market Sentiment**:
- The stock has experienced a recent sell candidate since June 14, 2024, and has seen a -17.15% decline in four weeks.
- There is a mixed signal from the short-term and long-term moving averages, with a buy signal from the former and a sell signal from the latter.

|code|stock code|stock name|last-price|last-change|Market Cap[20240702]|Market Cap rank[20240702]|market_code|
|---|---|---|---|---|---|---|---|
|MSFT|MSFT.O|Microsoft|459.2800|0.5583|3.4135094050683E12|1/6176|185|
|AAPL|AAPL.O|Apple|220.2700|1.6240|3.37763824214E12|2/6176|185|

3. **Technical Indicators**:
- The stock's 52-week range is $45.578 to $113.6, and the 200-day moving average is $79.55.
- The stock is currently trading below its 90-day and 200-day moving averages.

|code|stock code|stock name|last-price|last-change|Indication|Drug Name|FDA Review Round|Accelerated Approval Status|Accelerated Approval Pathway|FDA Approval Status|FDA Approval Event Type|FDA Review Date|market_code|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|AKBA|AKBA.O|Akebia Therapeutics|0.9600|-3.4205|Chronic kidney disease, Anemia, Kidney disease|Vafseo(Vadadustat)|1|Not Accelerated||Approved|PDUFA Date|20240327|186|
|AKBA|AKBA.O|Akebia Therapeutics|0.9600|-3.4205|Anemia, Chronic kidney disease, Kidney disease|Vafseo (Vadadustat)|1|Not Accelerated||Pending|PDUFA Date|20240327|186|
|ALDX|ALDX.O|Aldeyra Therapeutics|3.2500|0.0000|Dry eye syndrome|Reproxalap|1|Not Accelerated||Complete Response Letter|PDUFA Date|20231127|186|
|ALDX|ALDX.O|Aldeyra Therapeutics|3.2500|0.0000|Eye disease , Non-Hodgkin lymphoma, Chronic lymphocytic leukemia, Proliferative vitreoretinopathy|ADX-2191 (DHFR inhibitor)|1|Accelerated|Priority Review|Pending|PDUFA Date|20230621|186|
|ALNY|ALNY.O|Alnylam Pharmaceuticals|247.6100|1.7631|Transthyretin amyloidosis|ONPATTRO (Patisiran)|1|Not Accelerated||Pending|PDUFA Date|20231008|185|
|ALNY|ALNY.O|Alnylam Pharmaceuticals|247.6100|1.7631|Transthyretin amyloidosis|ONPATTRO (Patisiran)|1|Not Accelerated||Pending|FDA Adcomm|20230913|185|
|AMGN|AMGN.O|Amgen|310.7700|-0.0772|KRAS G12C-POSITIVE NSCLC|LUMAKRAS/LUMYKRAS|1|Accelerated|Accelerated Approval|Complete Response Letter|PDUFA Date|20231226|185|
|AMGN|AMGN.O|Amgen|310.7700|-0.0772|Non-small cell lung carcinoma|LUMAKRAS/LUMYKRAS Copy|1|Accelerated|Accelerated Approval|Pending|FDA Adcomm|20231005|185|
|AMGN|AMGN.O|Amgen|310.7700|-0.0772|Small cell lung cancer, Lung cancer, Cancer|Tarlatamab (AMG 757)|1|Accelerated|Priority Review|Approved|PDUFA Date|20240516|185|
|AMGN|AMGN.O|Amgen|310.7700|-0.0772|B-cell acute lymphoblastic leukemia|BLINCYTO(blinatumomab)|1|Accelerated|Priority Review|Approved|PDUFA Date|20240621|185|

4. **Future Outlook**:
- The stock is considered undervalued by some analysts, with an intrinsic value of $114.80.
- However, the stock's beta suggests that it may face exaggerated price declines in a bearish market.

|code|stock code|stock name|last-price|last-change|Future Policy Benefits[20220930]|Future Policy Benefits[20221231]|Future Policy Benefits[20230331]|Future Policy Benefits[20230630]|Future Policy Benefits[20230930]|Future Policy Benefits[20231231]|Future Policy Benefits[20240331]|Future Policy Benefits[20240630]|market_code|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|PRU|PRU.N|Prudential Financial|118.5500|0.8679|2.78262E11|2.61773E11|2.73586E11|2.68649E11|2.53551E11|2.73281E11|2.7279E11||169|
|MFC|MFC.N|Manulife Financial|26.4300|0.4943|2.7118237439280002E11|2.6967779968768E11|2.7977522946588E11|2.788467345405E11|2.6228666497635E11|2.8769277353388E11|2.8294977949816E11||169|
|MET|MET.N|MetLife|70.0400|0.2290|1.99671E11|1.87222E11|1.91741E11|1.90474E11|1.81755E11|1.96406E11|1.91013E11||169|
|BRK.B|BRK.B.N|Berkshire Hathaway B|407.1000|0.4714|1.50613E11|1.6264E11|1.62957E11|1.63086E11|1.62299E11|1.65942E11|1.63714E11||169|
|BRK.A|BRK.A.N|Berkshire Hathaway A|610668.0000|0.0341|1.50613E11|1.6264E11|1.62957E11|1.63086E11|1.62299E11|1.65942E11|1.63714E11||169|
|AIG|AIG.N|American|75.3300|1.1277|1.32785E11|1.27081E11|1.30639E11|1.25974E11|1.21489E11|1.28969E11|1.29045E11||169|
|SLF|SLF.N|Sun Life Financial|48.9600|0.4926|1.0029741162584001E11|9.702482964364E10|9.92458404719E10|9.756877244595E10|9.225932794070999E10|1.0276397505231E11|9.963737112795999E10||169|
|CB|CB.N|Chubb|255.5700|0.2943|8.5578E10|8.6223E10|8.6199E10|8.7544E10|9.2814E10|9.401E10|9.4716E10||169|
|AFL|AFL.N|Aflac|89.4300|0.4155|7.9145E10|8.8442E10|9.1522E10|8.6148E10|7.8697E10|8.3979E10|7.8211E10||169|
|CRBG|CRBG.N|Corebridge Financial|29.5900|1.6140|5.5407E10|5.0518E10|5.3406E10|5.4288E10|5.0355E10|5.7108E10|5.7587E10||169|

Given these points, while there is potential for growth in the long term, based on the average price targets and intrinsic value estimates, the short-term outlook seems cautious due to recent sell signals and the potential for market volatility. Investors should consider these factors when making investment decisions for Aptiv.